Stay updated with breaking news from Pegylated Interferon Lambda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In a recent study published in The New England Journal of Medicine, researchers used the TOGETHER platform trial protocol to perform a phase III randomized controlled trial (RCT) to evaluate the effectiveness of pegylated interferon (IFN) lambda (λ) therapy in outpatients with coronavirus disease 2019 (COVID-19) in Canada and Brazil.
It involves one dose of pegylated interferon lambda, a synthetic version of a naturally occurring protein that infected cells secrete to defend against viral infection
'The data look quite promising and other treatments have now fallen by the wayside,' said Paul Sax, MD, of Brigham and Women's Hospital in Boston.
/PRNewswire/ -- Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...